COLUMBIA, Md., March 19, 2019 /PRNewswire/ -- ACell, Inc. today announced that it has entered into an exclusive distributionagreement with MyungMoon Bio Co. Ltd. MyungMoon is a leading manufacturer and distributor of medical devices and pharmaceutical products in South Korea.
The terms of the distribution agreement grant exclusive
"South Korea is one of the largest healthcare markets in the Asia Pacific, and this agreement will meet a growing unmet need for innovative wound management solutions in the country," said Nino Pionati, ACell Vice President, International and Business Development. "We are excited about this partnership, and the opportunity to bring ACell's regenerative products to the patients and clinicians of South Korea."
"Our Cytal and MicroMatrix wound management devices facilitate remodeling of healthy, functional tissue in a range of complex and hard-to-heal wounds, said ACell CEO Patrick McBrayer. "This agreement expands access to these products even further across the globe, and continues ACell's path towards becoming the global leader in complex wound care."
"MyungMoon Bio is very fortunate to become a business partner of ACell, which is opening new horizons in regenerative medicine. MyungMoon Bio, equipped with solid organization and sales capacity in the South Korean market, will lay the groundwork for ACell to achieve early success in the Asian region", said MyungMoon Bio President, Mr. Sha—Joung Chang.
About ACell, Inc. ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing, and commercialization of medical devices for wound management and surgical soft tissue repair. ACell is committed to becoming and remaining an innovative leader in regenerative medical technology, offering superior healing options for doctors and patients. ACell is a privately held company and operates manufacturing facilities in Columbia, MD and Lafayette, IN. For more information about ACell please visit www.acell.com.
About MyungMoon Bio Co. LtdMyungMoon Bio is a leading manufacturer and distributor of medical device and pharmaceutical products in South Korea. The company develops medicines and medical supplies for the treatment of incurable disease and introduces excellent therapeutic products to the Korean market through strong partnership with global healthcare providers. MyungMoon Bio aspires to be the most respected company to improve the quality of patients' lives.
View original content:http://www.prnewswire.com/news-releases/acell-enters-exclusive-south-korean-distribution-agreement-for-wound-management-product-line-300814050.html
SOURCE ACell, Inc.
Subscribe to our Free Newsletters!